Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: leave off (275), cease (36)

Radiotherapy for pituitary tumours - patient information

Description: This booklet contains information for patients who have been recommended radiotherapy treatment for a pituitary tumour.
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Radiotherapy-for-pituitary-tumours-3290-PIL.pdf

Annual-report-2017-18

Description: ANNUAL REPORT AND ACCOUNTS 2017/18 incorporating the quality account 2017/18 Presented to Parliament pursuant to
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2017-181.pdf

Female pelvis radiotherapy - patient information

Description: This factsheet explains what to expect during your radiotherapy treatment to the female pelvis.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Female-pelvis-radiotherapy-1415-PIL.pdf

Lung stereotactic ablative body radiotherapy (SABR) - patient information

Description: This factsheet explains what lung stereotactic ablative body radiotherapy (SABR) is and what to expect during treatment.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Lung-stereotactic-ablative-body-radiotherapy-SABR-2091-PIL.pdf

Total body irradiation (TBI) - patient information

Description: This factsheet explains what to expect at your TBI treatment appointments.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Total-body-irradiation-TBI-1332-PIL.pdf

Apalutamide v1

Description: Chemotherapy Protocol PROSTATE APALUTAMIDE Regimen  Prostate cancer Indication  Apalutamide is recommended for non-metastatic prostate cancer as defined by recent imaging
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Apalutamide-v1.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Pembrolizumab (200mg)

Description: Regimen Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (200mg) • Head and Neck – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended in in adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-200mg.pdf

Pembrolizumab (400mg) head and neck

Description: Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (400mg) Regimen • Head and Neck – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended in in adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-400mg-head-and-neck.pdf

Pulmonary vein isolation radiofrequency ablation - patient information

Description: Patient information factsheet Pulmonary vein isolation (PVI) ablation Your doctor has recommended you have the ab
Url: /Media/UHS-website-2019/Patientinformation/Heartandlungs/Pulmonaryveinisolationradiofrequencyablation-725-PIL.pdf

171 to 180 of 209

Previous … 16 17 18 19 20 … Next